Grufity logo
Grufity logo
PNT

PNT - POINT Biopharma Global Inc. Stock Price, Fair Value and News

$63.90-1.36 (-2.08%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

Price Targets

PNT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PNT Price Action

Last 7 days

3.7%

Last 30 days

3.7%

Last 90 days

-14.9%

PNT RSI Chart

PNT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PNT Valuation

Market Cap

6.5B

Price/Earnings (Trailing)

66.84

Price/Sales (Trailing)

28.48

EV/EBITDA

43.09

Price/Free Cashflow

69.59

PNT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

PNT Fundamentals

PNT Revenue

PNT Earnings

PNT Profitability

Free Cashflow Yield

1.44%

PNT Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2023----
2022---226.6M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About POINT Biopharma Global Inc.

PNT
POINT Biopharma Global Inc., a radiopharmaceutical company, develops and commercializes radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-alpha inhibitor targeting program being developed for use in various tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.
 CEO
 WEBSITEpointbiopharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES129

POINT Biopharma Global Inc. Frequently Asked Questions

PNT is the stock ticker symbol of POINT Biopharma Global Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of POINT Biopharma Global Inc. is 6.45 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, PNT's PE ratio (Price to Earnings) is 66.84 and Price to Sales (PS) ratio is 28.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PNT PE ratio will change depending on the future growth rate expectations of investors.